Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 01/07/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 446 publications
A rare case of isolated lung metastases in prostate cancer.
Journal: Hellenic journal of nuclear medicine
Published: November 17, 2025
Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).
Journal: Future oncology (London, England)
Published: November 11, 2025
Unexpected Fatal Pneumocystis Jirovecii Pneumonia During Triplet Therapy for Hormone-Sensitive Prostate Cancer.
Journal: Respirology case reports
Published: October 31, 2025
Strategic Nanosuspension of Darolutamide for Enhanced Dissolution, Bioavailability, and Potentiated Prostate Cancer Treatment: Insights from Multiscale Computational Modeling.
Journal: ACS applied bio materials
Published: October 22, 2025
French recommendations from the AFU Cancer Committee for prostate cancer: 2025 summary of changes.
Journal: The French journal of urology
Published: October 06, 2025
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial.
Journal: European urology oncology
Published: September 22, 2025
Rapid Eradication of Extensive Spinal Metastases in a Prostate-Cancer Patient Taking Androgen-deprivation Therapy, Chemotherapy, and Oral Recombinant Methioninase on a Low-Methionine Diet.
Journal: Anticancer research
Published: September 12, 2025
Cost-effectiveness analysis of eight first-line treatments for metastatic hormone-sensitive prostate cancer in China.
Journal: Frontiers in pharmacology
Published: August 13, 2025
Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment.
Journal: International journal of molecular sciences
Published: August 12, 2025
Cost-effectiveness analysis of second-generation androgen receptor antagonists for the treatment of metastatic hormone-sensitive prostate cancer.
Journal: Frontiers in public health
Published: August 05, 2025
The addition of darolutamide to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.
Journal: Clinical advances in hematology & oncology : H&O
Published: July 29, 2025
Last Updated: 01/07/2026